| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg after 2 and 4 weeks' placebo run‐in; 8‐week double‐blind treatment |
| Participants |
Candesartan 8 mg: n=85(63 males,22 females); mean age=51(11) years: baseline sitting SBP=161.8(14.1) mm Hg, DBP=102.1(4.6) mm Hg; standing SBP=159.0(18.4) mm Hg, DBP=104.1(9.8) mm Hg;
Placebo: n=83(54 males,29 females); mean age=52(10) years; baseline sitting SBP=161.5(16.3) mm Hg, DBP=102.1(5.2) mm Hg; standing SBP=157.5(18.7) mm Hg, DBP=102.5(8.9) mm Hg |
| Interventions |
Candesartan 8 mg once daily;
Placebo;
take in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using fully automatic device (Omron HEM‐705CP);
Mean change from baseline in trough standing SBP/DBP using fully automatic device (Omron HEM‐705CP);
WDAE |
| Notes |
BP change and 95% CI of change reported, endpoint BP and SD not reported, baseline SD reported; 95% CI of change values are not appropriate; imputed baseline SBP SD for SBP SD of change, imputed overall trial mean DBP SD of change; BP data from Figure 1a, p. 20; Jadad score=5; funding source= Astra Hassle AB |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
